Article
Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.
The Journal of allergy and clinical immunology - 1 Sept 2010
Jin Ying, Hu Donglei, Peterson Edward L, Eng Celeste, Levin Albert M, Wells Karen, Beckman Kenneth, Kumar Rajesh, Seibold Max A, Karungi Gloria, Zoratti Amanda, Gaggin John, Campbell Janis, Galanter Joshua, Chapela Rocío, Rodríguez-Santana José R, Watson H Geoffrey, Meade Kelley, Lenoir Michael, Rodríguez-Cintrón William, Avila Pedro C, Lanfear David E, Burchard Esteban G, Williams L Keoki
Abstract excerpt
BACKGROUND: Inhaled corticosteroids (ICSs) are considered first-line treatment for persistent asthma, yet there is significant variability in treatment response. Dual-specificity phosphatase 1 (DUSP1) appears to mediate the anti-inflammatory action of corticosteroids. OBJECTIVE: We sought to determine whether variants in the DUSP1 gene are associated with clinical response to ICS treatment. METHODS: Study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
